xRead - September 2022

Wise et al.

Page 315

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study Year LOE Study design Study groups Clinical endpoint Conclusion Demoly et al. 696 2013 2b Observational cohort AR (n = 990) VAS, RQLQ, TSS 20% mild intermittent, 17% mild persistent, 15% moderate-severe intermittent, 48% moderate severe persistent. VAS can detect QOL variations with high sensitivity. de la Hoz Caballer et al. 697 2012 2b Observational cross-sectional Primary care patients (n = 616) SF-36, generic HRQOL, WPAI AR impacts productivity to a greater magnitude than hypertension and DM type II, but not depression. Meltzer et al. 698 2012 2b Observational cross-sectional Nasal allergy (n = 522); no nasal allergy (n = 400) Nonvalidated phone interview questions AR patients rate overall health lower, have worse sleep function, and decreased productivity than those with non-AR. Ciprandi et al. 699 2010 2b Observational cohort AR undergoing SLIT (n = 167) RQLQ QOL is significantly affected by AR. SLIT effective at improving QOL and symptoms. Stull et al. 682 2009 2b Observational cross-sectional AR (n = 404) Symptom scale, nocturnal RQLQ, WPAI, MOS-12 Sleep, PANAS-X cross-sectional Nasal congestion is more strongly correlated to outcomes, but ocular symptoms can have significant impact of QOL. Cadario et al. 683 2008 2b RCT AR treated with SLIT (n = 40) Nonvalidated QOL scale cohort Petersen et al. 700 2008 2b Observational

QOL is significantly affected by AR. SLIT improves QOL and symptoms.

AR (n = 248); AR and asthma (n = 121) RQLQ; 15D AR patients have worsened QOL during allergen exposure. 15D generates more comprehensive view of impact on QOL than RQLQ. 1 SLIT (n = 19); 2 Placebo (n = 15)

AR (n = 123) RQLQ QOL is significantly affected by AR. >2 sensitivities, eosinophil count, and nasal flow related to QOL. Eye symptoms correlate most strongly to QOL. RQLQ QOL is significantly affected by AR. SLIT improved QOL compared to placebo. 1 SAR (n = 83); 2 Asthma (n = 52)

Female gender, rural residence, and lower education levels associated with worse QOL in SAR.

SAR (n = 33) SF-36, SAT-P QOL is significantly affected by AR during peak season. 1 AR and asthma (n = 76); 2 AR but not asthma (n = 240); 3 Neither AR or asthma (n = 349) 40)

SF-36 Both asthma and AR impact QOL. AR impacts emotional and mental health, social activities, and activities of daily living. Comorbid asthma caused more physical limitations than AR alone.

Desloratadine + montelukast improves nasal obstruction and QOL.

Mini-RQLQ, SF-12 QOL is significantly affected by SAR and asthma. Acoustic rhinometry, RQLQ

cohort

cohort

cross-sectional

Ciprandi et al. 701 2007 2b Observational

Di Rienzo et al. 702 2006 2b RCT, double-blind AR (n = 34): Laforest et al. 703 2005 2b Observational

Majani et al. 691 2001 2b Observational

Leynaert et al. 689 2000 2b Observational

Cingi et al. 704 2013 2c Outcomes research PAR treated with desloratadine and montelukast (n =

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.